Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIN-102 in Adrenomyeloneuropathy (X-linked Adrenoleukodystrophy) – Randomized Placebo-Controlled Phase 2 Trial with Open-Label Extension
2017-000748-16Phase 2Unknown
- Sponsor
- Minoryx Therapeutics
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in adrenomyeloneuropathy (AMN) and adrenoleukodystrophy (ALD) comparing MIN-102 with Placebo (2 arms). Primary endpoint: Primary endpoints (main study). Status: unknown.
02
Drugs
leriglitazone
03
Conditions
adrenomyeloneuropathy (AMN)adrenoleukodystrophy (ALD)
Beyond the preview
Go deeper on 2017-000748-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000748-16.